L'esperienza che insegna
Non cammina bene, ha “tremori” e gli occhi sembra che danzino...
A child with gait abnormalities myoclonus and dancing eyes...
Massimo Grassi1, Francesco De Leonardis1, Paola Muggeo1, Michela Sesta2, Guglielmo Paradies3, Nicola Santoro1
1UO di Pediatria “F. Vecchio”; 2UO di Neurologia Pediatrica; 3UO di Chirurgia Pediatrica Azienda Ospedaliera Universitaria Policlinico Consorziale, Ospedale Giovanni XXIII, Bari
Settembre 2014 - pagg. 445 -450
Abstract
The paper reports the case of a 15-month-old girl who presented with abnormalities of
gait, myoclonus and opsoclonus. Paediatric opsoclonus-myoclonus syndrome is associated
in more than 50% to a neuroblastoma, generally with favorable prognosis. Stage 2B
neuroblastoma was diagnosed. The resection of the tumor, the immunosuppressive therapy
and a physiotherapy rehabilitation programme have enabled to achieve a good outcome.
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Gambini C, Conte M, Bernini G, et al. Neuroblastic
tumors associated with opsoclonusmyoclonus
syndrome: histological, immunoistochemical
and molecular features of 15 Italian
cases. Virchows Arch 2003;442:555-62.
2. Matthay KK, Blaes F, Hero B, et al. Opsoclonus
myoclonus syndrome in neuroblastoma a
report from a workshop on the dancing eyes
syndrome at the advances in neuroblastoma
meeting in Genoa, Italy, 2004. Cancer Lett
2005; 228:275-82.
3. Rothenberg AB, Berdon WE, D’Angio GJ,
Yamashiro DJ, Cowles RA. The association
between neuroblastoma and opsoclonus-myoclonus
syndrome: a historical review. Pediatr
Radiol 2009;39:723-6.
4. Ziter FA, Bray PF, Cancilla PA. Neuropathologic
findings in a patient with neuroblastoma
and myoclonic encephalopathy. Arch Neurol
1979;36:51.
5. Antunes NL, Khakoo Y, Matthay KK, et al.
Antineuronal antibodies in patients with neuroblastoma
and paraneoplastic opsoclonusmyoclonus.
J Pediatr Hematol Oncol 2000;22:
315-20.
6. Noetzel MJ, Cawley LP, James VL, Minard
BJ, Agrawal HC. Anti-neurofilament protein antibodies
in opsoclonus-myoclonus. J Neuroimmunol
1987;15:137-45.
7. Fisher PG, Wechsler DS, Singer HS. Anti-Hu
antibody in a neuroblastoma-associated paraneoplastic
syndrome. Pediatr Neurol 1994;10:
309-12.
8. Connolly AM, Pestronk A, Mehta S, Pranzatelli
MR 3rd, Noetzel MJ. Serum autoantibodies
in childhood opsoclonus-myoclonus syndrome:
an analysis of antigenic targets in neural
tissues. J Pediatr 1997;130:878-84.
9. Pranzatelli MR, Travelstead AL, Tate ED, et
al. B- and T-cell markers in opsoclonus-myoclonus
syndrome: immunophenotyping of CSF
lymphocytes. Neurology 2004;62:1526-32.
10. Fühlhuber V, Bick S, Kirsten A, et al. Elevated
B-cell activating factor BAFF, but not
APRIL, correlates with CSF cerebellar autoantibodies
in pediatric opsoclonus-myoclonus
syndrome. J Neuroimmunol 2009; 210:87-91.
11. Pranzatelli MR. The immunopharmacology
of the opsoclonus-myoclonus syndrome. Clin
Neuropharmacol 1996;19:1-47.
12. Pranzatelli MR. The neurobiology of the
opsoclonus-myoclonus syndrome. Clin Neuropharmacol
1992;15:186-228.
13. Rudnick E, Khakoo Y, Antunes NL, et al.
Opsoclonus-myoclonus ataxia syndrome in
neuroblastoma: clinical outcome and antineuronal
antibodies-a report from the Children’s
Cancer Group Study. Med Pediatr Oncol 2001;
36:612-22.
14. Altman AJ, Baehner RL. Favorable prognosis
for survival in children with coincident
opso-myoclonus and neuroblastoma. Cancer
1976;37:846-52.
15. Venturelli C, Guerra A, Paolucci P, Iughetti
L. Dancing eye syndrome as first symptom
of neuroblastoma. Acta Biomed 2013;84:162-6.
16. Koh PS, Raffensperger JG, Berry S, et al.
Long-term outcome in children with opsoclonus-
myoclonus and ataxia and coincident neuroblastoma.
J Pediatr 1994;125:712-6.
17. Brissaud HE, Beauvais P. Opsoclonus and
neuroblastoma. N Engl J Med 1969;280:1242.
18. Blake J, Fitzpatrick C. Eye signs in neuroblastoma.
Trans Ophthalmol Soc UK 1972;92:
825-33.
19. Conte M. La sindrome opso-mioclonica. Hematology
Meeting Report 2008;2(7):72-4.
20. Mitchell WG, Davalos-Gonzalez Y, Brumm
VL, et al. Opsoclonus-ataxia caused by childhood
neuroblastoma: developmental and neurologic
sequelae. Pediatrics 2002;109:86-98.
21. Catsman-Berrevoets CE, Aarsen FK, van
Hemsbergen ML, van Noesel MM, Hakvoort-
Cammel FG, van den Heuvel-Eibrink MM. Improvement
of neurological status and quality of
life in children with opsoclonus myoclonus syndrome
at long-term follow-up. Pediatr Blood
Cancer 2009;53:1048-53.
22. Hayward K, Jeremy RJ, Jenkins S, et al.
Long-term neurobehavioral outcomes in children
with neuroblastoma and opsoclonusmyoclonus-
ataxia syndrome: relationship to
MRI findings and anti-neuronal antibodies. J
Pediatr 2001;139:552-9.
23. Pohl KR, Pritchard J, Wilson J. Neurological
sequelae of the dancing eye syndrome. Eur J
Pediatr 1996;155:237-44.
24. Plantaz D, Michon J, Valteau-Couanet D,
et al. Opsoclonus-myoclonus syndrome associated
with non-metastatic neuroblastoma.
Long-term survival. Study of the French Society
of Pediatric Oncologists. Arch Pediatr
2000;7:621-8.
25. Gorman MP. Update on diagnosis, treatment,
and prognosis in opsoclonus-myoclonus-
ataxia syndrome. Curr Opin Pediatr 2010;
22(6):745-50.
26. Pranzatelli MR, Tate ED, Verhulst SJ, et
al. Pediatric dosing of rituximab revisited: serum
concentrations in opsoclonus-myoclonus
syndrome. J Pediatr Hematol Oncol
2010;32:e167-72.
Corrispondenza: grassimassimo@hotmail.it